改善慢性特发性便秘与便秘型肠易激综合征患者结局的真实世界治疗策略
慢性特发性便秘与便秘型肠易激综合征是复杂且相互重叠的疾病。一线治疗通常包括纤维和OTC渗透性泻药,但许多患者疗效不足。处方促分泌剂或5-羟色胺能药物通常更受青睐,尤其对合并腹痛和/或腹胀者。初始处方治疗失败后,可考虑重新尝试既往治疗、联合不同类别药物或辅助治疗,并应通过医患共同决策制定个体化方案。
要点
- 一线纤维和OTC渗透性泻药对许多慢性特发性便秘和便秘型肠易激综合征患者疗效不足。
- 处方促分泌剂或5-羟色胺能药物通常更受青睐,合并腹痛和/或腹胀者可能获益更大。
- 初始处方治疗失败后,可考虑重新尝试既往治疗、联合不同类别药物或辅助治疗。
核心结论
- 应根据患者与执业者共同决策制定个体化治疗,并主动监测和管理患者以最大化临床结局。
研究设计与样本
- 本文为针对慢性特发性便秘与便秘型肠易激综合征治疗策略的综述,检索范围原文未报告。
主要发现
- 一线治疗通常包括纤维和OTC渗透性泻药,但这些对许多个体不足。
- 一线选项失败后,通常更青睐处方促分泌剂(普卡那肽、利那洛肽、鲁比前列酮和替纳帕诺[待商业可及])或5-羟色胺能药物(普芦卡必利和替加色罗)。
- 合并腹痛和/或腹胀的个体可能从处方治疗中获得更大的整体改善,因为这些药物已被证明可减少合并的腹部和肠道症状。
关键数值与推荐
- 初始处方治疗失败时,可考虑重新尝试既往治疗(若初始试验不充分)、联合替代类别的药物或使用辅助治疗。
- 治疗应通过患者与执业者之间的共同决策进行个体化。
临床怎么用
- 临床应主动监测和管理患者以最大化临床结局,并通过医患共同决策制定个体化方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic idiopathic constipation and irritable bowel syndrome with constipation are complex, overlapping conditions. Although multiple guidelines have informed healthcare providers on appropriate treatment options for patients with chronic idiopathic constipation and irritable bowel syndrome with constipation, little direction is offered on treatment selection. First-line treatment options usually include fiber and over-the-counter osmotic laxatives; however, these are insufficient for many individuals. When these options fail, prescription secretagogues (plecanatide, linaclotide, lubiprostone, and tenapanor [pending commercial availability]), or serotonergic agents (prucalopride and tegaserod) are generally preferred. Individuals experiencing concurrent abdominal pain and/or bloating may experience greater overall improvements from prescription therapies because these agents have been proven to reduce concurrent abdominal and bowel symptoms. Should initial prescription treatments fail, retrying past treatment options (if not adequately trialed initially), combining agents from alternative classes, or use of adjunctive therapies may be considered. Given the broad spectrum of available agents, therapy should be tailored by mutual decision-making between the patient and practitioner. Overall, patients need to be actively monitored and managed to maximize clinical outcomes.
引用
- Brenner DM, Harris LA, Chang CH, et al. Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. Am J Gastroenterol. 2022. PMID: 35354772. doi:10.14309/ajg.0000000000001709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。